Stockscreener 앱 받기
2.87
1.03%
-0.03
시간 외 거래:
2.90
0.03
+1.05%
Prime Medicine Inc 주식(PRME)의 최신 뉴스
Ocular Therapeutix vs. Prime Medicine: A 2026 Analysis of Medical Innovation StocksNews and Statistics - IndexBox
Ocular Therapeutix vs. Prime Medicine: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
PRME Q1 2026 Earnings: EPS Misses Estimates Amid Ongoing Development ProgramsEPS Guidance Update - newsline.com
Prime Medicine's Prime Editing Is Worth The Risk (NASDAQ:PRME) - Seeking Alpha
Prime Drink Group announces private placement up to C$2.2M By Investing.com - Investing.com Australia
Prime Drink Group announces private placement up to C$2.2M - Investing.com UK
Prime Medicine (PRME) Holds Steady Near Support as Gene Editing Stock Seeks DirectionBlue Chip Entry Points - newsline.com
PRME Price Today: Prime Medicine, Inc. Stock Price, Quote & Chart | MEXC - MEXC
Transcript : Prime Medicine, Inc. Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026, Jun-10-2026 10 - marketscreener.com
Prime Medicine Stockholders Reaffirm Board and Auditor Choices - TipRanks
Prime Medicine (PRME) awards director David Schenkein 75,000 stock options - Stock Titan
Prime Medicine (PRME) director receives 75,000 options at $3.06 - Stock Titan
Prime Medicine (PRME) director and 10% owner receives 75,000-share option grant - Stock Titan
Prime Medicine (PRME) director receives 75,000-share stock option grant - Stock Titan
Prime Medicine (PRME) awards director 75,000 stock options at $3.06 - Stock Titan
Prime Medicine (PRME) director receives 75,000 stock options at $3.06 - Stock Titan
[Form 4] Prime Medicine, Inc. Insider Trading Activity - Stock Titan
Prime Medicine (PRME) shareholders elect Class I directors and ratify PwC as 2026 auditor - Stock Titan
Is Prime Medicine (NASDAQ:PRME) In A Good Position To Deliver On Growth Plans? - Moomoo
PRME Q1 2026 Earnings: EPS Misses Estimates as Pre-Commercial Biotech Continues R&D FocusROA Comparison - newsline.com
PRME News | PRIME MEDICINE INC (NASDAQ:PRME) - ChartMill
We're Keeping An Eye On Prime Medicine's (NASDAQ:PRME) Cash Burn Rate - Yahoo Finance
Prime Medicine, Inc. (PRME) Reports Q4 Loss, Misses Revenue Estimates - Eastern Progress
Prime Medicine CEO to speak at Goldman Sachs Healthcare Conference on June 10, 2026 - Pluang
Prime Medicine to Present at Goldman Sachs 47th Annual Global Healthcare Conference - The Manila Times
Prime Medicine Inc. Gains 4.41% as Gene Editing Stock Tests Key ResistanceMax Pain Level - The Legal Advocate
PRME Q1 2026 Earnings: Wider-than-Expected Loss but Positive Stock Reaction Amid Pipeline ProgressDiluted EPS Report - newsline.com
Prime Medicine (PRME) Gains Ground as Shares Approach Key ResistanceGap Up Stocks - newsline.com
Prime Medicine to Present at Jefferies Global Healthcare Conference - The Manila Times
Prime Medicine CEO to speak at Jefferies Healthcare Conference on June 4, 2026 - Pluang
Prime Medicine (PRME) Surges Over 11% as Gene Editing Stock Finds Support Near $3.13Factor Valuation - The Legal Advocate
PRME - Finviz
Prime Medicine Inc. (PRME) Q1 2026 Earnings: Wider-than-Expected Loss Highlights Pre-Revenue Development PhaseEPS Estimate Trend - The Legal Advocate
PRME Q1 2026 Earnings: EPS Worse Than Expected as Pre-Revenue Biotech Advances PipelinePro Level Trade Signals - Newser
PRME Q1 2026 Earnings: EPS Misses Estimates as Pre-Revenue Biotech Focuses on Pipeline Progress - Newser
Prime Medicine (PRME) Q1 2026 Disappoints — EPS $-0.28 Below $-0.26 ViewsEarnings Turnaround - Newser
Prime Medicine slips after Q4 updates - MSN
Prime Medicine (PRME) Reports Q1 EPS - Yahoo Finance
10 Best Penny Stocks to Buy Before They Explode - Insider Monkey
Oppenheimer Maintains Prime Medicine(PRME.US) With Buy Rating, Announces Target Price $11 - Moomoo
TradingKey - TradingKey
Prime Medicine, Inc. (PRME) reports Q1 loss, misses revenue estimates - MSN
Number of shareholders of Prime Medicine, Inc. – NASDAQ:PRME - TradingView
LifeSci Capital Maintains Prime Medicine(PRME.US) With Buy Rating, Maintains Target Price $6 - Moomoo
PRME Prime Medicine revenue jumps 55% YoY in Q1; shares rally 3% on growth momentum.Management Guidance - newser.com
JonesTrading Initiates Prime Medicine(PRME.US) With Buy Rating, Announces Target Price $5 - Moomoo
H.C. Wainwright Maintains Prime Medicine(PRME.US) With Hold Rating - Moomoo
The opportunity most miss about Prime Medicine (PRME) (-8.65%) 2026-05-08Value Factor - newsline.com
Prime Medicine Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Prime Medicine (NASDAQ:PRME) Q1 Results Show Revenue Miss and Narrower Loss as Key Pipeline Milestones Loom - ChartMill
PRIME MEDICINE ($PRME) Releases Q1 2026 Earnings - Quiver Quantitative
[10-Q] Prime Medicine, Inc. Quarterly Earnings Report - Stock Titan
Prime Medicine Q1 net loss narrows as R&D expenses fall - TradingView
Prime Medicine (Nasdaq: PRME) Q1 2026 results, cash runway into 2027 and pipeline update - Stock Titan
Prime Medicine Reports First Quarter 2026 Financial Results and Provides Business Updates - The Manila Times
Prime Medicine targets 2 liver disease filings in 2026, data due 2027 - Stock Titan
Top Prime Medicine (PRME) Competitors 2026 - MarketBeat
1.27%
1.43%
자본화:
|
볼륨(24시간):